The Oncology Institute, Inc. Common Stock (TOI) is a publicly traded Healthcare sector company. As of July 10, 2026, TOI trades at $5.85 with a market cap of $564.90M and a P/E ratio of -10.75. TOI moved +3.36% today. Year to date, TOI is +64.33%; over the trailing twelve months it is +141.74%. Its 52-week range spans $0.13 to $6.11. Analyst consensus is strong buy with an average price target of $7.67. Rallies surfaces TOI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
The Oncology Institute Secures $86M Refinancing and Price Target Lifted to $9: BTIG raised its price target on The Oncology Institute to $9.00 from $8.00 and reaffirmed its Buy rating after the company refinanced an $86 million convertible note with a $75 million term loan and $11 million cash payment. Analysts forecast a 50% reduced quarterly loss of $0.07 and 30.3% revenue growth to $156.15 million.
| Metric | Value |
|---|---|
| Price | $5.85 |
| Market Cap | $564.90M |
| P/E Ratio | -10.75 |
| EPS | $-0.54 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.11 |
| 52-Week Low | $0.13 |
| Volume | 1.89M |
| Avg Volume | 0 |
| Revenue (TTM) | $502.73M |
| Net Income | $-60.61M |
| Gross Margin | 0.00% |
3 analysts cover TOI: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.67.